Segment Information (Tables)

9 Months Ended

Sep. 30, 2023

Summarized financial information for the Company’s segments is shown in the following tables:


(in thousands)	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
Revenue
Patient services	$	53,634	$	44,627	$	157,333	$	118,793
Dispensary	26,792		18,839		76,228		57,736
Clinical trials & other	1,609		1,511		4,890		4,530
Consolidated revenue	$	82,035	$	64,977	$	238,451	$	181,059

Direct costs
Patient services	$	44,961	$	36,126	$	132,653	$	96,379
Dispensary	21,072		15,738		60,328		47,816


(in thousands)	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
Clinical trials & other	24		113		276		400
Total segment direct costs	$	66,057	$	51,977	$	193,257	$	144,595

Depreciation expense
Patient services	$	749	$	316	$	1,601	$	848
Dispensary	30		—		75		—
Clinical trials & other	1		1		1		4
Total segment depreciation expense	$	780	$	317	$	1,677	$	852

Amortization of intangible assets
Patient services	$	731	$	688	$	2,082	$	1,995
Dispensary	—		—		—		—
Clinical trials & other	53		53		158		158
Total segment amortization	$	784	$	741	$	2,240	$	2,153

Operating income
Patient services	$	7,193	$	7,497	$	20,997	$	19,571
Dispensary	5,690		3,101		15,825		9,920
Clinical trials & other	1,531		1,344		4,455		3,968
Total segment operating income	$	14,414	$	11,942	$	41,277	$	33,459

Goodwill impairment charges
Patient services	$	—	$	—	$	16,235	$	—
Dispensary	—		—		—		—
Clinical trials & other	—		—		632		—
Total impairment charges	$	—	$	—	$	16,867	$	—

Selling, general and administrative expense	$	28,205	$	31,963	$	85,761	$	90,117
Non-segment depreciation and amortization	134		76		379		214
Total consolidated operating loss	$	(13,925)	$	(20,097)	$	(61,730)	$	(56,872)